Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.

@article{Hortobagyi1998LongtermPO,
  title={Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.},
  author={Gabriel N Hortobagyi and Rachel Leigh Theriault and Allan Lipton and Lucy Porter and Douglas W. Blayney and Clive Sinoff and Helen Wheeler and Joseph F. Simeone and John J Seaman and Robert D Knight and Michael Heffernan and K Mellars and Dirk J. Reitsma},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1998},
  volume={16 6},
  pages={2038-44}
}
PURPOSE Pamidronate, an aminobisphosphonate, has been shown to lower the risk of skeletal complications associated with lytic bone lesions for up to 1 year in women with stage IV breast cancer who received chemotherapy. We studied the long-term effectiveness and safety of continued treatment with intravenous pamidronate infusions for up to 2 years. PATIENTS AND METHODS Three hundred eighty-two women with metastatic breast cancer and lytic bone lesions who received chemotherapy were randomly… CONTINUE READING
Highly Influential
This paper has highly influenced 12 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 191 extracted citations

Similar Papers

Loading similar papers…